Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2h sec.gov
Orgenesis Inc. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2018 ORGENESIS INC. (
ORGS

0
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-07-17 sec.gov
Orgenesis Inc.: Form 8K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2018 ORGENESIS INC. (Exact name of registrant as specified in
ORGS

0
ORGS / Orgenesis, Inc. FORM NT 10-Q

2018-07-17 sec.gov
Orgenesis Inc.: Form 12b-25 - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):
ORGS

0
Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018

2018-07-17 globenewswire
GERMANTOWN, Md., July 17, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal second quarter ended May 31, 2018.
ORGS

0
ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)

2018-07-17 sec.gov
Orgenesis Inc.: Form 10-Q - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 31, 2018 or [ ] TRANSITION
ORGS

0
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-07-05 sec.gov
Orgenesis Inc. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2018 ORGENESIS INC.<
ORGS

1
Orgenesis Forms Strategic Partnership with Leading Healthcare Fund and Reports Planned Investment of up to $25 Million into MaSTherCell Subsidiary

2018-06-29 globenewswire
Consolidates Global CDMO Business Including Belgian Subsidiary MaSTherCell S.A., Israeli Partner Atvio Biotech and Korean Partner Curecell Co.
ORGS

2
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-06-29 sec.gov
Orgenesis Inc.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2018 ORGENESIS INC.
ORGS

1
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-06-25 sec.gov
Orgenesis Inc.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2018 ORGENESIS INC.
ORGS

1
Orgenesis Inc. Added to Russell Microcap® Index

2018-06-25 globenewswire
GERMANTOWN, Md., June 25, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that it has been added to the FTSE Russell Microcap® Index effective at the market open today, June 25.
ORGS

1
Orgenesis CDMO Partner Atvio Biotechnology’s CEO to Present on Roundtable at the 2018 BIO International Convention

2018-06-04 globenewswire
GERMANTOWN, Md., June 04, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or “the Company”), a manufacturer, service provider, and developer of advanced cell therapies, announced today that their Israeli Contract Development and Manufacturing Organization (CDMO) partner, Atvio Biotechnology, will be featured on a roundtable at the 2018 BIO International Convention being held June 4 - 7 in Boston, Massachusetts.
ORGS

187
Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside.
LZAGY MKGAF PFZ C O6Z MS.PRE CRSP MS.PRF MS.PRG MS.PRA PFIZER BAC CDMO MS.PRI MKGAY MS.PRK 4502 MS ORGS 500680 PFE WXXWY LZAGF

1
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-05-18 sec.gov
Orgenesis Inc.: Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2018 ORGENESIS INC.
ORGS

1
Orgenesis and Atvio Biotechnology to Present at the World Advanced Therapies & Regenerative Medicine Congress

2018-05-16 globenewswire
GERMANTOWN, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS), a manufacturer, service provider and developer of advanced cell therapies, announced today that the Company, along with its CDMO partner, Atvio Biotechnology (Atvio) based in Israel, will be featured on two panels at the World Advanced Therapies & Regenerative Medicine Congress being held May 16 - 18 in London. The World Advanced Therapies and Regenerative Medicine Congress includes both a world-class conference where business leaders from around the world meet and a unique exhibition for pharmaceutical, biotech and research experts.
ORGS

1
ORGS / Orgenesis, Inc. FORM 8-K (Current Report)

2018-04-30 sec.gov
Orgenesis Inc. - Form 8-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2018 ORGENESIS INC. (Exact name of registrant as specif
ORGS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 68619K105